324 177

Selective Depletion of SSEA-3- and TRA-1-60-Positive Undifferentiated Human Embryonic Stem Cells by Magnetic Activated Cell Sorter (MACS)

Authors
 Hyun Ok Kim  ;  Yong Joon Huh  ;  Jiho Jang  ;  Youjung Choi  ;  Dong-Wook Kim  ;  Han-Soo Kim 
Citation
 Tissue Engineering and Regenerative Medicine (조직공학과 재생의학), Vol.8(2) : 253-261, 2011 
Journal Title
 Tissue Engineering and Regenerative Medicine  (조직공학과 재생의학) 
ISSN
 1738-2696 
Issue Date
2011
Abstract
The capacity of indefinite self-renewal and pluripotency make human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) an attractive source for potential regenerative medicine. However, teratoma formation is one of the major obstacles for implementing hESC-based therapeutics in a clinical setting. While this tumorigenic capacity is known to be lost upon lineage differentiation in vitro, there is a potential risk that any residual undifferentiated hESCs or progenitor cells may form tumors upon transplantation. To ensure the safety of hESCs in clinical application, we thus explored the magnetic activated cell sorter (MACS) as a tool for separating undifferentiated hESCs from a mixed population of hESCs and human blood mononuclear cells. Labeled with single or combinations of two fluorsecein-labeled monoclonal antibodies (SSEA-3 and TRA-1-60) and subsequently stained with anti-FITC and/or anti-PE magnetic microbeads, cells were subjected to MACS separation. While a reduction of hESCs by depletion with a single marker was observed, there was still a significant fraction of residual hESCs in the flow-through fraction. However, two consecutive MACS separations upon simultaneous staining of two different hESC markers, SSEA-3 and TRA-1-60, completely depleted hESCs, as validated by flow cytometer, real-time PCR and immunofluoresence microscopic analyses. The maximum efficacy of hESC removal using this protocol was higher than 99.9%. No teratoma formation was observed in hESC-depleted cell injection to NOD/SCID mice. These results indicate that the current MACS protocol with two antibodies can efficiently eliminate undifferentiated cells from differentiated cells and greatly alleviate concerns about tumor formation by hESC-derived cellular therapeutics
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/92763
Files in This Item:
T201100508.pdf Download
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Physiology (생리학교실)
Yonsei Authors
김동욱(Kim, Dong Wook) ORCID logo https://orcid.org/0000-0002-5025-1532
김한수(Kim, Han Soo)
김현옥(Kim, Hyun Ok)
장지호(Jang, Ji Ho)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse